“New drugs & regimens: drug screening and improving the predictive value of preclinical models” – TTU TB, Deutsches Zentrum für Infektionsforschung (DZIF), BMBF, 2021-2025
“Validation of the confirmed γ-glutamylspermine synthetase GlnA3 as a target for development of novel anti-tubercular drugs” - Sub project: "Relevance of the γ-glutamylspermine synthetase GlnA3 for successful growth inhibition of M. tuberculosis" (GSS-TUBTAR) – BMBF, Programm: Targetvalidierung für die pharmazeutische Wirkstoffentwicklung II, 2021-2023
“Isolation and Characterization of M. tuberculosis-induced lipid droplets from human primary macrophages“; Leibniz Center Infection (LCI), 2018-2021
“Discovering new therapeutic targets and drugs to combat AMR tuberculosis: proteomics characterization and drug screening of mycobacterium-infected macrophages" – Olav Thon Foundation, Norwegen (in Kooperation with T. Flo (N), M. Lerm (SE) und K. Prasad (IND), 2018-2022
„Exploiting the methylerythritol phosphate pathway as a source of drug targets for novel anti-infectives“ - MepAnti - Marie Skodowska-Curie Innovative Training Networks, 2020-2024
„NaPAnti: Development of natural product-based antibacterials targeting the sliding clamp DnaN“ - Bundesministerium für Bildung und Forschung, 2019-2022
„InhibitMycoRex: Optimization of mycobacterial thioredoxin reductase inhibitors, novel lead compounds against M. tuberculosis“ – Deutsches Zentrum für Infektionsforschung, 2019-2021
„ETBRA: European tuberculosis regimen accelerator“ – EU / Horizon 2020 (IMI), 2020-
Projects